Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

Nivolumab plus ipilimumab with chemotherapy provides long-term OS benefit over chemotherapy alone in all randomized patients with metastatic NSCLC



Nivolumab plus ipilimumab with chemotherapy provides long-term OS benefit over chemotherapy alone regardless of tumor PD-L1 expression (<1% or ≥1%) or histology (squamous or nonsquamous)

	PD-L1 <1%		PD-L1 ≥1%		Squamous		Nonsquamous	
	NIVO + IPI + chemo (n=135)	Chemo (n=129)	NIVO + IPI + chemo (n=204)	Chemo (n=204)	NIVO + IPI + chemo (n=115)	Chemo (n=112)	NIVO + IPI + chemo (n=246)	Chemo (n=246)
Median OS, mo (95% CI)	17.7 (13.7–20.3)	9.8 (7.7–13.5)	15.8 (13.8–22.2)	10.9 (9.5–13.2)	14.5 (13.1–19.3)	9.1 (7.2–11.6)	17.8 (14.1–20.7)	12.0 (9.9–13.9)
HR (95% CI)	0.66 (0.50–0.86)		0.74 (0.60–0.92)		0.64 (0.48–0.84)		0.80 (0.66–0.97)	
4-y OS rate, % (95% CI)	23 (16–30)	13 (8–20)	21 (16–27)	16 (11–22)	20 (13–28)	10 (5–16)	22 (17–27)	19 (14–24)

- In an exploratory efficacy analysis of patients who discontinued all components of nivolumab plus ipilimumab with chemotherapy due to treatment-related adverse events, the 4-year OS rate was 41%
- Safety was consistent with prior reports, and no new safety signals were observed

Overall, nivolumab plus ipilimumab with chemotherapy continued to demonstrate long-term, durable efficacy benefit versus chemotherapy alone as a first-line therapy in patients with metastatic or recurrent NSCLC regardless of tumor PD-L1 expression or histology and further support its use as an efficacious first-line treatment option particularly for patients with tumor PD-L1 <1% or squamous histology, populations with high unmet needs

David P. Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, Manuel Cobo, Stephanie Bordenave, Oscar Juan-Vidal, Juliana Menezes, Niels Reinmuth, Eduardo Richardet, Ying Cheng, Hideaki Mizutani, Enriqueta Felip, Bogdan Zurawski, Aurelia Alexandru, Luis Paz-Ares, Shun Lu, Thomas John, Xiaoqing Zhang, Javed Mahmood, Nan Hu, Tuli De, Irene Santi, John R. Penrod, Yong Yuan, Adam Lee, Martin Reck